TY - JOUR
T1 - Topical microbicides to prevent HIV
T2 - Clinical drug development challenges
AU - Hendrix, Craig W.
AU - Ying, Jun Cao
AU - Fuchs, Edward J.
PY - 2009
Y1 - 2009
N2 - Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.
AB - Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.
KW - Adverse events
KW - Antiretroviral drugs
KW - Clinical trial simulation
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Pre-exposure prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=65249168098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65249168098&partnerID=8YFLogxK
U2 - 10.1146/annurev.pharmtox.48.113006.094906
DO - 10.1146/annurev.pharmtox.48.113006.094906
M3 - Review article
C2 - 19006450
AN - SCOPUS:65249168098
SN - 0362-1642
VL - 49
SP - 349
EP - 375
JO - Annual Review of Pharmacology and Toxicology
JF - Annual Review of Pharmacology and Toxicology
ER -